Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Caris Life Sciences (CAI) EBITDA Margin (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of EBITDA Margin data on record, last reported at 28.05% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 5656.0% year-over-year to 28.05%; the TTM value through Dec 2025 reached 1.08%, changed N/A, while the annual FY2025 figure was 8.3%, 6008.0% up from the prior year.
  • EBITDA Margin reached 28.05% in Q4 2025 per CAI's latest filing, up from 241.67% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 483.36% in Q2 2024 and bottomed at 241.67% in Q3 2025.